|

Personalized Synthetic Long Peptide Vaccine Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Personalized SLP Vaccine, TSMA-based SLP Vaccine, TSMA-based Synthetic Long Peptide Vaccine, Tumor Specific Mutant Antigen-based Synthetic Long Peptide Vaccine

Pipeline

Phase 2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Metastatic Triple-Negative Breast Carcinoma1
  • Anatomic Stage IV Breast Cancer AJCC v81
  • Invasive Breast Carcinoma1
  • Breast Cancer1
  • Cancer1

Orange, California1 trial

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.